Novel Regimens in COVID-19 Treatment

Launched by TANTA UNIVERSITY · May 7, 2020

Keywords

ClinConnect Summary

This clinical trial is studying new treatments for COVID-19 using two medications: nitazoxanide and ivermectin. Both of these drugs have shown promise in helping to fight the virus that causes COVID-19. The goal of the trial is to see how effective these medications are in treating patients with COVID-19, particularly in those who may be experiencing more severe symptoms.

To participate in this trial, individuals must be between the ages of 65 and 74 and have a confirmed COVID-19 infection. However, people who have allergies to either of the medications or cannot take them for other medical reasons will not be eligible. If you join the trial, you can expect to receive either nitazoxanide or ivermectin, and the research team will monitor your health closely throughout the study. This trial is currently looking for participants, and it offers a chance to contribute to important research that could help improve treatments for COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with COVID-19 infection
• Exclusion Criteria:
• • Allergy or contraindication to the drugs.